NTLA
Intellia Therapeutics, Inc.
Key Financials
Operating Income
$-440990000
↑ 17.5%
Net Income
$-412694000
↑ 20.5%
Total Assets
$842.1M
↓ 29.3%
Revenue
$67.7M
↑ 16.9%
EPS (Diluted)
$-3.81
↑ 27.4%
Total Liabilities
$170.7M
↓ 46.5%
Shareholders' Equity
$671.4M
↓ 23.0%
Cash & Equivalents
$155.5M
↓ 17.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/10/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 424B5 | 3/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NTLA |
| Company Name | Intellia Therapeutics, Inc. |
| CIK | 1652130 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-285-6200 |